In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation


VEgetaRian Diet in patients with Ischemic heart disease (VERDI): An open-label, randomized, prospective, cross-over study

Session Poster Session 7

Speaker Demir Djekic

Congress : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Nutrition, Malnutrition and Heart Disease
  • Session type : Poster Session
  • FP Number : P6208

Authors : D Djekic (Orebro,SE), F Carlsson (Uppsala,SE), R Landberg (Uppsala,SE), C Sarnqvist (Orebro,SE), Y Cao (Stockholm,SE), V Tremaroli (Gothenburg,SE), F Backhed (Gothenburg,SE), O Frobert (Orebro,SE)

D Djekic1 , F Carlsson2 , R Landberg2 , C Sarnqvist1 , Y Cao3 , V Tremaroli4 , F Backhed4 , O Frobert1 , 1Orebro University Hospital, Orebro University, Department of Cardiology - Orebro - Sweden , 2Swedish University of Agricultural Sciences - Uppsala - Sweden , 3Karolinska Institute, Unit of Biostatistics, Institute of Environmental Medicine - Stockholm - Sweden , 4Sahlgrenska Academy, Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at University of Gothenburg - Gothenburg - Sweden ,


Background: A vegetarian diet (VD) in patients diagnosed with ischemic heart disease (IHD) may reduce future cardiovascular risk.

Purpose: The study hypothesis was that patients diagnosed with IHD can benefit from a VD assessed by multiple risk markers for this type of disease.

Methods: In a crossover study patients diagnosed with IHD, treated by percutaneous coronary intervention and on optimal medical therapy were randomly allocated to a 4-week intervention with ready-made (lunch and dinner) isocaloric VD or meat diet (MD). The primary outcome was change in oxidized low-density lipoprotein cholesterol (LDL-C) levels. Secondary outcomes were difference in changes of blood lipids, weight, body mass index (BMI), blood pressure, heart rate, glycated haemoglobin (HbA1c), number of participants reaching guideline target values, quality of life, gut microbiota, and trimethylamine N-oxide between the two interventions.

Results: 31 participants were recruited (median age: 67 years, male sex: 93.5%). Significant between-intervention differences (VD vs MD) were found in oxidized LDL-C (-2.73 U/L; p=.015), total cholesterol (TC) (-0.13 mmol/L, p=.01), LDL-C (-0.10 mmol/L; p=.02), weight (-0.67 kg, p=.008) and BMI (-0.21 kg/m2, p=.009). After VD, numerically more subjects reached guideline LDL-C target values (87% vs 77%) but this did not reach statistical significance (p=.07). During VD intervention the diet led to a significant reduction in oxidized LDL-C, TC, LDL-C, HDL-C, ApoB, and ApoB/ApoA1 ratio.

Conclusions: Our results suggest that in patients with IHD a VD compared to a MD, lowers oxidative stress, improves lipid profile and lowers BMI.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are